PIQUR is a Swiss clinical-stage pharmaceutical company incorporated in August 2011 as a spin-off of the University of Basel, focusing on the discovery and development of innovative anti-cancer drugs based on lipid kinase (PI3K) and mTOR inhibition. PIQUR’s pipeline originates from one of the most promising research areas in oncology. Both PI3K and mTOR are clinically validated drug targets in oncology.
PIQUR’s lead compound, PQR309, is a novel, balanced pan-class 1 PI3K/mTOR inhibitor formulated for oral administration. Preclinical studies demonstrated that PQR309 is a highly selective kinase inhibitor, penetrating blood-brain barrier with potent in vitro as well as in vivo antitumor activity. A first-in-man clinical Phase 1 study was successfully completed and the maximum tolerated dose has been determined and has shown promising activity. PQR309 is currently engaged in multiple Phase 1 and Phase 2 studies as a single agent and as combination therapy.
Location: Switzerland, Basel-City, Basel
Employees: 11-50
Total raised: $31.43M
Investors 2
| Date | Name | Website |
| - | Venture Ki... | venturekic... |
| - | VentureLab | venturelab... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 20.07.2015 | - | $19M | - |
| 08.04.2014 | - | $12.43M | Versant Ve... |
Mentions in press and media 22
| Date | Title | Description | Source |
| 30.07.2019 | PIQUR kicks-off second clinical trial | Founded in 2011 as a spin-off of the University of Basel, Switzerland, PIQUR Therapeutics is a cli... | startuptic... |
| 24.06.2019 | New CEO for PIQUR | Melanie Rolli joined PIQUR in 2017 as Chief Medical Officer and took on additional responsibilitie... | startuptic... |
| 27.04.2017 | Additional milestone for PIQUR's lead compound | Diffuse large B-cell lymphoma (DLBCL) is an aggressive form of lymphoma, and the most common type ... | startuptic... |
| 11.01.2017 | Eli Lilly, Merck add new combo alliance; Gilead really... | • Eli Lilly is taking its newly approved cancer drug Lartruvo and combining it with Keytrud... | endpts.com... |
| 14.09.2016 | Top 100 Swiss startups have been revealed | Every year, distinguished 100 experts from various industries nominate their favourite startups of... | startuptic... |
| 19.02.2016 | Eisai and PIQUR sign landmark collaboration agreement | The Phase 1/2b study is scheduled to begin in early 2016. The initial Phase 1 dose-escalation part... | startuptic... |
| 11.02.2016 | Anmeldung für den Jungunternehmerpreis Nordwestschweiz 2016 ... | Nach der erfolgreichen vierten Austragung des Preises im Jahr 2014 haben sich die Verantwortlichen... | startuptic... |
| 20.07.2015 | PIQUR Therapeutics raises CHF 18 Million in Series A2 financ... | PIQUR Therapeutics AG, a Swiss clinical-stage pharmaceutical company focused on the discovery and de... | venturekic... |
| 20.07.2015 | PIQUR Therapeutics raises CHF 18 Million in Series A2 financ... | PIQUR Therapeutics raises CHF 18 Million in Series A2 financing 20.07.2015 17:00, Lara Rossi linkedI... | venturelab... |
| 20.07.2015 | Piqur Therapeutics Closes $19M Series A2 Financing | Piqur Therapeutics AG, a Basel, Switzerland-based clinical-stage pharmaceutical company focused on t... | finsmes.co... |
Show more